TRPV5 and osteoporosis: Similarly, Alendronate, another TRPV5 inhibitor, has been shown to enhance bone mineral density and quality in patients with osteoporosis through the inhibition of TRPV5-mediated Ca2+ transmembrane transport (Nijenhuis et al., 2008).